INCY

INCY

USD

Incyte Corp. Common Stock

$102.920+1.560 (1.539%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$101.360

الأعلى

$103.860

الأدنى

$100.020

الحجم

2.74M

أساسيات الشركة

القيمة السوقية

20.2B

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

2.00M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $53.56الحالي $102.920الأعلى $103.86

أخبار ذات صلة

Analyst Upgrades

Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102

Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.

عرض المزيد
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
GlobeNewswire

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with

عرض المزيد
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Analyst Upgrades

Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target

Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.

عرض المزيد
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
BusinessWire

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated

عرض المزيد
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
BusinessWire

Incyte to Present at Upcoming Investor Conferences

Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00

عرض المزيد
Incyte to Present at Upcoming Investor Conferences
GlobeNewswire

Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina

MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM

Analyst Upgrades

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84

RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.